Abstract
31 patients with multiple sclerosis were treated for a mean period of 4 years with high doses of human immunoglobulin. Overall, one third improved, one third showed no change and one third deteriorated. The effect of treatment was not related to any clinical or biological variable except perhaps the immunogenetic profile (HLA). The potential role of this symptomatic treatment is discussed.

This publication has 0 references indexed in Scilit: